In addition to PDL1 and CD27, other immune checkpoint inhibitors (ICIs) for treating advanced metastatic NSCLC include anti-PD-1 nivolumab and anti-CTLA4 ipilimumab [39]. This evidence concerns the gene CD27 and non-small cell lung carcinoma.